RxDoctor Payments Data

Terrance Posluszny, MD

Cardiovascular Disease · McAllen, TXNPI 1295738631

Payments from drug & device makers

$5,696in general payments, 2019–2025

Across 322 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Novartis$780
  • Merck$568
  • Pfizer$536
  • AstraZeneca$521
  • Boehringer Ingelheim$481
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$5,57798%
  • Education$1192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,696 in reported general payments places this provider in the 60th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$45,963
Medicare patients
190
Services billed
591

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan252$292,520
XareltoRivaroxaban82$92,155
EliquisApixaban74$80,195
FarxigaDapagliflozin Propanediol74$76,897
JardianceEmpagliflozin60$68,078
VerquvoVericiguat25$31,892
Repatha SureclickEvolocumab28$30,553
Ranolazine ErRanolazine316$25,712
Praluent PenAlirocumab12$9,460
DapagliflozinDapagliflozin Propanediol13$8,010
Ezetimibe217$6,152
NexletolBempedoic Acid15$5,705
Rosuvastatin Calcium278$4,199
Irbesartan159$3,796
Labetalol Hcl87$3,676

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$780$292,520252 claims
Johnson & JohnsonXarelto$1,061$92,15582 claims
PfizerEliquis$536$80,19574 claims
AstraZenecaFarxiga$521$76,89774 claims
Boehringer IngelheimJardiance$481$68,07860 claims
MerckVerquvo$568$31,89225 claims
Esperion Therapeutics, Inc.Nexletol$151$5,70515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →